The safety concerns regarding immune checkpoint inhibitors in liver cancer patients rising mainly from CHB

• Κύριοι συγγραφείς: Shike Lou (Συγγραφέας), Zhujun Cao (Συγγραφέας), Wanqing Chi (Συγγραφέας), Xiaoyin Wang (Συγγραφέας), Mingyang Feng (Συγγραφέας), Lanyi Lin (Συγγραφέας), Yezhou Ding (Συγγραφέας), Kehui Liu (Συγγραφέας), Lihong Qu (Συγγραφέας), Gangde Zhao (Συγγραφέας), Shisan Bao (Συγγραφέας), Hui Wang (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Frontiers Media S.A., 2023-04-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Aim: To analyze the safety of immune checkpoint inhibitors in primary liver cancer patients and to identify the risk factors for immune-related adverse events (irAEs).Methods: The study enrolled 106 patients with primary liver cancer, including 81 with hepatocellular carcinoma and 25 with intrahepat...